News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Exciting New Cancer Company, Angiogen, To Present At Midwest Venture Summit


10/19/2005 5:10:08 PM

CHICAGO, May 16 /PRNewswire/ -- Angiogen announced today that Mark Arizmendi, President, will be presenting at the Midwest Venture Summit on May 20, 2005, at the Chicago Marriott Magnificent Mile located at 540 North Michigan Avenue, Chicago. Mr. Arizmedi's presentation will focus on the company, its products and its clinical progress.

About Angiogen

Angiogen is a privately held biopharmaceutical discovery company developing novel therapies for treating cancerous solid, vascular tumors. Angiogen's scientific team has world-recognized expertise and experience in angiogenesis inhibition, especially as it relates to the disease of cancer. Angiogen's first therapy, currently in a Phase I clinical trial, is based upon combining two classes of FDA approved drugs into one anti-angiogenesis cancer- fighting treatment. Three major biopharmaceutical companies have provided support for Angiogen's clinical research. Angiogen continues to explore other diagnostic tests and drug candidates related to its work in angiogenesis field offering hope to the approximately 5 million people worldwide who will die annually from metastatic cancer (555,000 in US). For additional information on Angiogen, please visit our Website at: http://www.angiogenesis.com/ .

This press release contains forward-looking statements that involve a high degree of technological, regulatory, and competitive risks and uncertainties inherent in early stage biopharmaceutical companies.

Angiogen

CONTACT: Dorene Lynch for Angiogen, +1-847-754-7815, or Fax,+1-847-864-3291, dlynch@angiogenesis.com


Read at BioSpace.com


comments powered by Disqus
Angiogen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES